In today’s briefing:
- Analysis of Active Portfolio Ideas: Divestitures, Buyouts, Privatizations, and Strategic Reviews
- Oura IPO Alert: The Market Repriced It Early
- Aequitas: CSPC Innovation Pharma A/H Listing – 1H26’s Performance Boosted by Licensing Deal
- Sanofi Acquisition Of Regeneron: Could Dupixent & An $8 Billion Alliance Spark A Bigger Deal?
- Sunshine Biopharma (SBFM US): Synthetic Expert Call Transcript (05 Oct 2026)
- IPO Rating: TRex Bio, Inc.
- Allarity Acquisition (ALAQ US): Synthetic Expert Call Transcript (05 Oct 2026)
- TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO
- Cortina Completes 8% Buyback; Chandra Asri Adds to Hiap Seng Stake
- LOVE: Deepening Strategic Relationship with Curaleaf
Analysis of Active Portfolio Ideas: Divestitures, Buyouts, Privatizations, and Strategic Reviews
- Medtronic’s split-off offer for MiniMed Group expires October 9, with odd-lot holders prioritized and exempt from proration.
- Ingenia Communities received a takeover proposal from Warburg Pincus, with the latest offer at A$5.25/share under board review.
- Currency Exchange International shows 109% return, driven by a high-margin FX Payments business and potential US uplisting.
Oura IPO Alert: The Market Repriced It Early
- Oura pulled the deal the day before it was due to list.
- This is not uncommon and happens all the time, but not in the midst of the calmest tape imaginable: a VIX sitting at 15, US major indices at near-record highs, credit default swap (CDS) spreads holding in or narrowing, and a company that had spent a week insisting demand was strong.
- These would generally not lead to postponing an IPO, especially for a company that is profitable, growing, and in an industry (wellness) that has drawn a lot of buzz over the past few years.
Aequitas: CSPC Innovation Pharma A/H Listing – 1H26’s Performance Boosted by Licensing Deal
- CSPC Innovation Pharmaceutical-A (300765 CH) CSPC Innovation Pharma aims to raise around US$500m in its H-share listing.
- CSPC Innovation Pharmaceutical is engaged in the research, development, manufacturing, and sale of caffeine, functional ingredients, consumer nutritional products, and biopharmaceuticals.
- In this note, we talk about the company’s past performances.
Sanofi Acquisition Of Regeneron: Could Dupixent & An $8 Billion Alliance Spark A Bigger Deal?
- Sanofi has moved materially closer to Regeneron Pharmaceuticals (NASDAQ), although there is currently no disclosed takeover proposal or confirmed acquisition interest involving the U.S. biotechnology company.
- The latest development is an expanded immunology alliance announced on October 1, under which Sanofi will pay Regeneron $1 billion upfront and potentially another $7 billion tied to development, regulatory and commercial milestones.
- The companies will jointly develop four next-generation Regeneron antibodies, share development and commercialization costs equally, and split future global profits 50-50.
Sunshine Biopharma (SBFM US): Synthetic Expert Call Transcript (05 Oct 2026)
- Preclinical Oncology Overpromise: Despite aggressive press releases regarding the K1.1 mRNA program’s in vivo mouse data, the asset remains years away from human trials. Competing in the oncology mRNA space against well-capitalized giants is unrealistic for a company with Sunshine Biopharma’s current capital structure.
- Generic Margin Pressure and Regional Stagnation: Nora Pharma, the Canadian generics subsidiary, generates virtually all of Sunshine’s $36.31 million in FY2025 revenue. However, expanding beyond its historical Quebec stronghold into Ontario and Western Canada has proven low-margin due to intense competition from giants like Apotex and Teva, alongside structural pricing caps and pharmacy rebate (professional allowance) structures.
- Unrelenting Dilution and Listing Survival: Sunshine Biopharma’s commercial generic engine does not generate enough cash to self-fund the R&D pipeline. Instead, the company operates as a capital market survivalist, relying on serial equity dilution. With an accumulated deficit exceeding $75 million and consecutive reverse stock splits (1-for-10 in June 2026 and an authorized 1-for-20 in September 2026), the equity remains highly risky for fundamental investors.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
IPO Rating: TRex Bio, Inc.
- ✓ IPO Prophet Rating: 7.50/10 🏦 Deal Quality & Underwriters: 8.20/10. TRex Bio is offering 8.33 million all-primary shares at $14.00-$16.00, targeting approximately $125 million at the midpoint, with Nasdaq trading under TRXB expected after pricing on October 9, 2026.
- J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush provide a strong healthcare-focused underwriting group.
- Deal quality is reinforced by collaborations with Eli Lilly and Janssen, backing from established biotechnology investors and Lilly’s non-binding indication of interest in purchasing approximately $13 million of the offering.
Allarity Acquisition (ALAQ US): Synthetic Expert Call Transcript (05 Oct 2026)
- High Selectivity in the 2026 Biotech Market: While biotech venture funding and traditional IPO markets have rebounded sharply from the “biotech winter”—with $23 billion raised in venture capital and over 23 US-listed IPOs raising ~$7.3 billion as of late September 2026—capital is highly concentrated. Pre-crossover and non-venture-backed companies face a steep uphill battle, driving them toward alternative listing vehicles like SPACs.
- The Structuring and Dilution Reality for Allarity: Targeting a $300 million to $500 million enterprise value sweet spot with its proposed $100 million trust, Allarity Acquisition Corp faces tough PIPE and redemption dynamics (often 80% to 90% redemption rates). To close a deal, the sponsor will likely have to restructure its ~25.0% promote, subjecting a major portion to earn-outs or forfeiture.
- Differentiated Sourcing via DRP® and Clinical Infrastructure: Allarity’s competitive advantage lies in its proprietary Drug Response Predictor (DRP®) technology and newly CLIA-certified in-house lab, allowing it to act as an operational partner that can revive stalled or undervalued clinical-stage oncology assets, rather than operating merely as a financial shell.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO
- Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed.
- TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration.
- Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.
Cortina Completes 8% Buyback; Chandra Asri Adds to Hiap Seng Stake
- Over five sessions, directors reported 22 acquisitions and no disposals, while substantial shareholders recorded 28 acquisitions and five disposals.
- Cortina Holdings completed a S$55 million share buyback, reducing issued shares excluding treasury shares to 152,332,142.
- Chandra Asri Trading increased its stake in Hiap Seng Industries to 16.18% through a S$2.76 million off-market transaction.
LOVE: Deepening Strategic Relationship with Curaleaf
- Cannara expanded its long-term international supply agreement with Curaleaf, lifting the potential contract value to $34M over a two-year term, up from $21M under the original July agreement (+62%).
- The upsizing comes just two months after supply began on August 1st, which we view as a strong validation of LOVE’s flower quality.
- The Company now has 15 of 24 grow rooms active at Valleyfield (vs. 14 at Q3/26), with a fully funded buildout plan through FY29.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
